EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands

Micha J Pilz, Simon Seyringer, Lára R Hallsson, Andrew Bottomley, Femke Jansen, Madeleine T King, Richard Norman, Marianne J Rutten, Irma M Verdonck-de Leeuw, Peter D Siersema, Eva Maria Gamper

The European Journal of Health Economics · 2024

DOI: 10.1007/s10198-024-01670-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, 2024. Verfasst von Micha J Pilz und 10 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital of Psychiatry II, Medical University Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Neoplasms, Quality of Life, Technology Assessment, Biomedical. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Organisation for Research and Treatment of Cancer, University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cost-utility analysis typically relies on preference-based measures (PBMs). While generic PBMs are widely used, disease-specific PBMs can capture aspects relevant for certain patient populations. Here the EORTC QLU-C10D, a cancer-specific PBM based on the QLQ-C30, is validated using Dutch trial data with the EQ-5D-3L as a generic comparator measure.

Methods

We retrospectively analysed data from four Dutch randomised controlled trials (RCTs) comprising the EORTC QLQ-C30 and the EQ-5D-3L. Respective Dutch value sets were applied. Correlations between the instruments were calculated for domains and index scores. Bland–Altman plots and intra-class correlations (ICC) displayed agreement between the measures. Independent and paired t -tests, effect sizes and relative validity indices were used to determine the instruments’ performance in detecting clinically known-group differences and health changes over time.

Results

We analysed data from 602 cancer patients from four different trials. In overall, the EORTC QLU-C10D showed good relative validity with the EQ-5D-3L as a comparator (correlations of index scores r = 0.53–0.75, ICCs 0.686–0.808, conceptually similar domains showed higher correlations than dissimilar domains). Most importantly, it detected 63% of expected clinical group differences and 50% of changes over time in patients undergoing treatment. Both instruments showed poor performance in survivors. Detection rate and measurement efficiency were clearly higher for the QLU-C10D than for the EQ-5D-3L.

Conclusions

The Dutch EORTC QLU-C10D showed good comparative validity in patients undergoing treatment. Our results underline the benefit that can be achieved by using a cancer-specific PBM for generating health utilities for cancer patients from a measurement perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisNeoplasmsQuality of LifeTechnology Assessment, BiomedicalHumansNetherlandsMaleFemaleMiddle AgedRetrospective StudiesAgedRandomized Controlled Trials as TopicQuality-Adjusted Life YearsAdultReproducibility of ResultsSurveys and QuestionnairesPatient Preference

Stichwörter der Autor:innen

Cancer-specific preference-based measureEORTC QLU-C10DEQ-5D-3LResponsivenessValidity

Autor:innen und Institutionen

  • University Hospital of Psychiatry II, Medical University Innsbruck, Innsbruck, Austria.
  • Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL - University for Health Sciences a…
  • Department of Nuclear Medicine, Medical University of Innsbruck, 6020, Innsbruck, Austria.
  • Quality of Life Department, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Department Otolaryngology-Head and Neck Surgery, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Treatment and Quality of Life, Amsterdam, The Netherlands.

Förderung

  • European Organisation for Research and Treatment of Cancer
  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Pilz, M. J., Seyringer, S., Hallsson, L. R., Bottomley, A., Jansen, F., King, M. T., Norman, R., Rutten, M. J., Verdonck-de Leeuw, I. M., Siersema, P. D., & Gamper, E. M. (2024). The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01670-6

Vancouver

Pilz MJ, Seyringer S, Hallsson LR, Bottomley A, Jansen F, King MT, et al. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands. The European Journal of Health Economics. 2024. doi:10.1007/s10198-024-01670-6

BibTeX
@article{Pilz2024,
  author = {Pilz, Micha J and Seyringer, Simon and Hallsson, Lára R and Bottomley, Andrew and Jansen, Femke and King, Madeleine T and Norman, Richard and Rutten, Marianne J and Verdonck-de Leeuw, Irma M and Siersema, Peter D and Gamper, Eva Maria},
  title = {The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands},
  journal = {The European Journal of Health Economics},
  year = {2024},
  doi = {10.1007/s10198-024-01670-6}
}
Kostenlos starten →